Quote | Spruce Biosciences Inc. (NASDAQ:SPRB)
Last: | $0.5252 |
---|---|
Change Percent: | 0.97% |
Open: | $0.52 |
Close: | $0.5252 |
High: | $0.5338 |
Low: | $0.5104 |
Volume: | 475,312 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | Spruce Biosciences Inc. (NASDAQ:SPRB)
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Busines...
Pairs Spruce’s Investigational Product Candidate, Tildacerfont, with HMNC’s Companion Diagnostic, the Proprietary Cortibon Genetic Selection Tool, to Treat MDD Patients Responsive to CRF 1 Receptor Antagonism Provides Spruce with Option to In-License Exclusive Worldwide ...
Message Board Posts | Spruce Biosciences Inc. (NASDAQ:SPRB)
Subject | By | Source | When |
---|---|---|---|
$SPRB MomentumIts gaining last trade up | pzottkpz | investorshub | 05/14/2023 3:01:39 AM |
$SPRB MomentumIts trading | TheFinalCD | investorshub | 05/14/2023 12:32:56 AM |
$SPRB Anyone hear anything lately? Want to see this one go | MiamiGent | investorshub | 05/11/2023 8:49:01 AM |
$SPRB Do we have a winner?Turn around time? | MiamiGent | investorshub | 05/10/2023 11:39:50 PM |
news out | pzottkpz | investorshub | 05/07/2023 8:29:52 PM |
News, Short Squeeze, Breakout and More Instantly...
Spruce Biosciences Inc. Company Name:
SPRB Stock Symbol:
NASDAQ Market:
Spruce Biosciences Inc. Website:
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Busines...
Pairs Spruce’s Investigational Product Candidate, Tildacerfont, with HMNC’s Companion Diagnostic, the Proprietary Cortibon Genetic Selection Tool, to Treat MDD Patients Responsive to CRF 1 Receptor Antagonism Provides Spruce with Option to In-License Exclusive Worldwide ...
Significant Reduction in Dehydroepiandrosterone Sulfate ( DHEAS) Versus Placebo Observed in Women with Elevated DHEAS Levels at Baseline Increase in Serum Sex Hormone Binding Globulin (SHBG) Versus Placebo Observed Tildacerfont was Well-Tolerated with No Safety Signals ...